Aurinia Offers A Lot Of Upside Potential With Upcoming Phase 2 Dry Eye Disease Study Readout [Seeking Alpha]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Seeking Alpha
Aurinia Offers A Lot Of Upside Potential With Upcoming Phase 2 Dry Eye Disease Study Readout Summary Aurinia Pharmaceuticals is expected to release results from its phase 2 dry eye disease study any day now in January of 2019. The global dry eye disease market is expected to reach $7.7 billion by 2025. Aurinia Pharmaceuticals has cash and cash equivalents of $138.9 million as of September 30, 2018, which means it has enough cash to fund its operations into 2020. Phase 3 results for the Lupus Nephritis study using voclosporin are set to be released in Q4 of 2019. AUPH Major Catalyst The biggest reason to look at Aurinia Pharmaceuticals now is because of the upcoming results for Voclosporin treating patients with dry eye disease. This is a phase 2 study that is recruiting 90 patients with this disease. Before diving into the details of this study, it's important to understand the underlying cause of the disease. Dry eye disease global dry eye disease market is going to be worth $7.7 bil
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder ValueBusiness Wire
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare ConferenceBusiness Wire
- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
AUPH
Earnings
- 5/2/24 - Beat
AUPH
Sec Filings
- 5/3/24 - Form ARS
- 5/3/24 - Form DEFA14A
- 5/3/24 - Form DEF
- AUPH's page on the SEC website